19 August 2024
The Russian Ministry of Health has granted permission to FMBA (Federal Medical-Biological Agency) to carry out the first and second phases of clinical trials for a recombinant vaccine aimed at preventing birch pollen allergy and cross-food allergies (apple, peach, peanut, soy).
The study will assess the effectiveness, safety, reactogenicity, and immunogenicity of the vaccine, as reported by the agency’s press service.
The preclinical studies of the vaccine have shown high effectiveness and safety. It did not exhibit toxic effects and did not cause damage to vital organs, even at a hundredfold excess of the dosage.
PrintOctober 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
DSM Group predicts the Russian pharmaceutical market will grow by 10% annually
18 October 2024
An extra 6.1 billion rubles will be allocated for drug provision in 2025
18 October 2024
Pharmasyntez to build heparin production plant in Tatarstan
17 October 2024
17 October 2024